Logo image of ASND

ASCENDIS PHARMA A/S - ADR (ASND) Stock Price, Quote, News and Overview

NASDAQ:ASND - Nasdaq - US04351P1012 - ADR - Currency: USD

172.06  +4.59 (+2.74%)

After market: 172.06 0 (0%)

ASND Quote, Performance and Key Statistics

ASCENDIS PHARMA A/S - ADR

NASDAQ:ASND (5/2/2025, 8:00:01 PM)

After market: 172.06 0 (0%)

172.06

+4.59 (+2.74%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High183
52 Week Low111.09
Market Cap10.35B
Shares60.12M
Float59.52M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PE133.67
Earnings (Next)09-01 2025-09-01/amc
IPO01-28 2015-01-28


ASND short term performance overview.The bars show the price performance of ASND in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 10 20 30

ASND long term performance overview.The bars show the price performance of ASND in the last 1, 2 and 3 years. 1 year 2 years 3 years 20 40 60 80 100

The current stock price of ASND is 172.06 USD. In the past month the price increased by 14.64%. In the past year, price increased by 25.41%.

ASCENDIS PHARMA A/S - ADR / ASND Daily stock chart

ASND Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 19.33 351.09B
AMGN AMGEN INC 13.55 151.20B
GILD GILEAD SCIENCES INC 13.4 129.08B
VRTX VERTEX PHARMACEUTICALS INC 1728.1 128.84B
REGN REGENERON PHARMACEUTICALS 13.67 65.39B
ARGX ARGENX SE - ADR 341.93 39.67B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 33.74B
ONC BEIGENE LTD-ADR N/A 27.57B
BNTX BIONTECH SE-ADR N/A 25.23B
NTRA NATERA INC N/A 21.30B
SMMT SUMMIT THERAPEUTICS INC N/A 20.72B
BIIB BIOGEN INC 7.81 18.10B

About ASND

Company Profile

ASND logo image Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates. The firm produces products for the treatments of growth hormone deficiency, endocrinology, central nervous system disorders, infectious diseases, and diabetes. The firm operates globally though its subsidiaries: Ascendis Pharma GmbH (Germany), Ascendis Pharma, Inc. (Delaware, United States), Ascendis Pharma Endocrinology, Inc. (Delaware, United States), Ascendis Pharma, Ophthalmology Division A/S (Denmark), Ascendis Pharma, Endocrinology Division A/S (Denmark), Ascendis Pharma Bone Diseases A/S (Denmark), Ascendis Pharma Growth Disorders A/S (Denmark) and Ascendis Pharma Oncology Division A/S (Denmark).

Company Info

ASCENDIS PHARMA A/S - ADR

Tuborg Boulevard 12

Hellerup 2900 DK

CEO: Jan Moller Mikkelsen

Employees: 1017

ASND Company Website

ASND Investor Relations

Phone: 4570222244

ASCENDIS PHARMA A/S - ADR / ASND FAQ

What is the stock price of ASCENDIS PHARMA A/S - ADR today?

The current stock price of ASND is 172.06 USD. The price increased by 2.74% in the last trading session.


What is the ticker symbol for ASCENDIS PHARMA A/S - ADR stock?

The exchange symbol of ASCENDIS PHARMA A/S - ADR is ASND and it is listed on the Nasdaq exchange.


On which exchange is ASND stock listed?

ASND stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for ASCENDIS PHARMA A/S - ADR stock?

23 analysts have analysed ASND and the average price target is 211.65 USD. This implies a price increase of 23.01% is expected in the next year compared to the current price of 172.06. Check the ASCENDIS PHARMA A/S - ADR stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is ASCENDIS PHARMA A/S - ADR worth?

ASCENDIS PHARMA A/S - ADR (ASND) has a market capitalization of 10.35B USD. This makes ASND a Large Cap stock.


How many employees does ASCENDIS PHARMA A/S - ADR have?

ASCENDIS PHARMA A/S - ADR (ASND) currently has 1017 employees.


What are the support and resistance levels for ASCENDIS PHARMA A/S - ADR (ASND) stock?

ASCENDIS PHARMA A/S - ADR (ASND) has a support level at 158.13 and a resistance level at 172.07. Check the full technical report for a detailed analysis of ASND support and resistance levels.


Is ASCENDIS PHARMA A/S - ADR (ASND) expected to grow?

The Revenue of ASCENDIS PHARMA A/S - ADR (ASND) is expected to grow by 86.27% in the next year. Check the estimates tab for more information on the ASND EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy ASCENDIS PHARMA A/S - ADR (ASND) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does ASCENDIS PHARMA A/S - ADR (ASND) stock pay dividends?

ASND does not pay a dividend.


When does ASCENDIS PHARMA A/S - ADR (ASND) report earnings?

ASCENDIS PHARMA A/S - ADR (ASND) will report earnings on 2025-09-01, after the market close.


What is the Price/Earnings (PE) ratio of ASCENDIS PHARMA A/S - ADR (ASND)?

ASCENDIS PHARMA A/S - ADR (ASND) does not have a PE ratio as the earnings reported over the last twelve months were negative (-6.51).


What is the Short Interest ratio of ASCENDIS PHARMA A/S - ADR (ASND) stock?

The outstanding short interest for ASCENDIS PHARMA A/S - ADR (ASND) is 6.95% of its float. Check the ownership tab for more information on the ASND short interest.


ASND Technical Analysis

ChartMill assigns a technical rating of 9 / 10 to ASND. When comparing the yearly performance of all stocks, ASND is one of the better performing stocks in the market, outperforming 93.5% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

ASND Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to ASND. ASND may be in some trouble as it scores bad on both profitability and health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

ASND Financial Highlights

Over the last trailing twelve months ASND reported a non-GAAP Earnings per Share(EPS) of -6.51. The EPS increased by 35.35% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -32.05%
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%36.06%
Sales Q2Q%-1.89%
EPS 1Y (TTM)35.35%
Revenue 1Y (TTM)36.34%

ASND Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 87% to ASND. The Buy consensus is the average rating of analysts ratings from 23 analysts.

For the next year, analysts expect an EPS growth of 44.29% and a revenue growth 86.27% for ASND


Ownership
Inst Owners110.13%
Ins Owners0.78%
Short Float %6.95%
Short Ratio8.07
Analysts
Analysts86.96
Price Target211.65 (23.01%)
EPS Next Y44.29%
Revenue Next Year86.27%